Clinical trials: psoriasis
Psoriasis
Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe Psoriasis
The purpose of this study is to determine whether teplizumab is safe when administered subcutaneously (by needle under the skin) in subjects with psoriasis.
- Trial name
- NCT00954915
- Testing
- teplizumab
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- MacroGenics
Psoriasi
Effect of Adalimumab Therapy on Psoriasis Patient
to evaluate the impact of adalimumab therapy on quality of life in patient with severe psoriasis.
- Trial name
- NCT05889338
- Testing
- adalimumab and methotrexate
- Where
- Egypt
- Volunteers
- 140 people
- Sponsor
- Sohag University
Psoriasis
HPP737 Substance Balance Study in Human
Main research purpose 1. Quantitative analysis of the total amount of radioactivity in excreta (urine and feces) of male healthy subjects after oral administration of [14C]HPP737, to obtain the cumulative excretion rate and main…
- Trial name
- NCT06584058
- Testing
- HPP737
- Where
- China
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Newsoara Biopharma Co., Ltd.
Axial Spondyloarthritis (AxSpA), Non-radiographic Evidence-AxSpA
A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers
The primary objectives of this study are to assess whether there is transfer of Certolizumab Pegol (CZP) into breast milk of lactating mothers who are receiving an established dosing regimen of CZP by evaluating the concentration…
- Conditions
- Axial Spondyloarthritis (AxSpA), Non-radiographic Evidence-AxSpA, Ankylosing Spondylitis, Crohn's Disease
- Trial name
- CRADLE (NCT02154425)
- Testing
- Breast milk sampling, Certolizumab Pegol
- Where
- 6 sites in United States, Netherlands and 1 more
- Volunteers
- 17 people
- Sponsor
- UCB BIOSCIENCES, Inc.
Osteoarthritis, Arthritis, Rheumatoid
Low Dose Naltrexone for Chronic Pain in Osteoarthritis and Inflammatory Arthritis
Over 100 million Americans report chronic pain. One of the most common causes of chronic pain is osteoarthritis (OA). OA is attributable to "wear and tear," but reasons for pain are complex.
- Conditions
- Osteoarthritis, Arthritis, Rheumatoid, Arthritis, Psoriatic
- Trial name
- NCT04115020
- Testing
- Naltrexone
- Where
- United States
- Sponsor
- Brigham and Women's Hospital
Safety Study for Future Treatment of Psoriasis
A Phase I, Double Blind, Randomized, Placebo Controlled, Maximal Dose Study to Determine the Safety, Tolerability of Topical Cream Containing MGC (Medical Grade Cannabis) in Healthy Volunteers
This single center, prospective, double-blind, placebo-controlled, randomized two parts study (part I and part II) will assess the safety of topical cream (3% CBD and 3% THC), applied twice daily (bid), in healthy subjects, for…
- Trial name
- NCT02976779
- Testing
- OWC MGC cream, OWC Control Cream
- Where
- Israel
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- One World Cannabis Ltd.
Plaque Psoriasis
A Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR-1139 Injection in Patients With Plaque Psoriasis
This study is a randomized, double-blind, multicenter, dose-parallel-controlled phase II clinical trial. The study consists of three stages: a 4-week screening period, a 52-week treatment period, and a 12-week follow-up period.
- Trial name
- NCT07758075
- Testing
- SHR-1139, SHR-1139 and SHR-1139 pleacebo
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Psoriasis
Etanercept Plus UVB-311nm Phototherapy in Psoriasis
Etanercept, a biological antipsoriatic drug with anti-tumor-necrosis factor (TNF) activity has been approved for the treatment of moderate to severe psoriasis.
- Trial name
- NCT00550030
- Testing
- UVB-311nm radiation, No treatment
- Where
- Austria
- Volunteers
- 6 people
- Sponsor
- Medical University of Graz
Psoriatic Arthritis, Axial Spondyloarthritis
A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults
To demonstrate that bimekizumab administered intravenously is noninferior to subcutaneous administration.
- Trial name
- NCT07290036
- Testing
- Bimekizumab regimen 1 iv, Bimekizumab regimen 2 iv, Bimekizumab regimen 3 sc
- Where
- 63 sites in United States, Bulgaria and 4 more
- Volunteers
- 392 people
- Sponsor
- UCB Biopharma SRL
Psoriasis
Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy
This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study designed to evaluate the efficacy and safety of apremilast (CC-10004) in subjects with mild to moderate plaque psoriasis.
- Trial name
- ADVANCE (NCT03721172)
- Testing
- Apremilast
- Where
- 64 sites in United States, Canada
- Volunteers
- 595 people
- Sponsor
- Amgen
Psoriasis, Skin Diseases
A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis
This is a dose-ranging study designed to investigate the efficacy and safety of Baricitinib in the treatment of participants with moderate to severe, chronic plaque psoriasis as assessed by the Psoriasis Area and Severity Index…
- Conditions
- Psoriasis, Skin Diseases, Skin Diseases, Papulosquamous
- Trial name
- NCT01490632
- Testing
- Baricitinib
- Where
- 35 sites in United States, Canada and 2 more
- Volunteers
- 271 people
- Sponsor
- Eli Lilly and Company
Psoriasis
FibroScan ® Study: Assessing Liver Fibrosis in Patients Using Methotrexate for Psoriasis
The purpose of this study is to validate FibroScan and FibroSURE™ as equal or superior alternatives to liver biopsy for the monitoring and detection of methotrexate-induced hepatic fibrosis and cirrhosis in patients with…
- Trial name
- NCT03820934
- Testing
- Fibroscan and Fibrosure
- Where
- United States
- Sponsor
- University Hospitals Cleveland Medical Center
Arthritis, Psoriatic
A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice
The purpose of this study is to evaluate treatment persistence with guselkumab and interleukin-17 inhibitor (IL-17i) initiated at enrollment into this study (PsABIOnd).
- Trial name
- PsABIOnd (NCT05049798)
- Testing
- Guselkumab, IL-17i
- Where
- 155 sites in Argentina, Australia and 18 more
- Volunteers
- 1,314 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Chronic Plaque Psoriasis
Phase II Efficacy Study Looking at a Single-dose of One of Three Dose Levels of AIN457 in Patients With Chronic Plaque-type Psoriasis
This is an exploratory, 4 arm, parallel group, placebo-controlled study comparing three doses of AIN457 to placebo. Subjects with a diagnosis of moderate to severe chronic plaque psoriasis will be randomized to receive either…
- Trial name
- NCT00770965
- Testing
- AIN457
- Where
- 5 sites in United States
- Volunteers
- 80 people
- Sponsor
- Novartis Pharmaceuticals
Scalp Psoriasis
Subject Preference for Scalp Psoriasis Treatment
The scalp is one of the most common affected sites in psoriatic patients as 79% of them have scalp involvement.It has also a psychological aspect with 31% of patients with scalp psoriasis indicating distress.
- Trial name
- NCT00438399
- Testing
- C. propionate - Corticosteroid 1, C. propionate- Corticosteroid 2, C. propionate -Corticosteroid 3
- Where
- Italy
- Volunteers
- 219 people
- Sponsor
- Galderma R&D
Psoriasis
A Study of HCXT-2001 Tablets and HCXT-2001 Tablets(A) in Healthy Adults
The goal of this intervention study is to assess the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of HCXT-2001 Tablets and HCXT-2001 Tablets(A) in Healthy Participants.
- Trial name
- NCT07792928
- Testing
- HCXT-2001 Tablets, HCXT-2001 Tablets(A)
- Where
- 3 sites in New Zealand
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Shanghai Peptidstar Therapeutics Limited
Healthy, Plaque Psoriasis
A Study to Investigate the Safety and Tolerability of CAN10 Antibody in Healthy Subjects and in Subjects With Plaque Psoriasis.
This is a first-in-human, randomized, double- blind, placebo-controlled, dose escalation study to investigate how different doses of CAN10 are tolerated, taken up by the body and how long CAN10 stays in the body.
- Trial name
- NCT06143371
- Testing
- CAN10
- Where
- Germany
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Psoriasis
A Study of Guselkumab in Naive or Bio-experienced Participants With Regional (Facial and Genital) Psoriasis
The purpose of this study is to investigate the effectiveness profile of guselkumab used in a real-life setting in participants with moderate facial and/or genital psoriasis.
- Trial name
- GULLIVER (NCT04439526)
- Testing
- Guselkumab
- Where
- 38 sites in Italy
- Volunteers
- 356 people
- Sponsor
- Janssen-Cilag S.p.A.
Psoriasis, Atopic Dermatitis
Tailored Patient-Provider Communication (TPPC): Evaluating the Impact of TPPC in Dermatology Patients
The impact of tailored patient-provider communication to improve clinical trial recruitment, patient knowledge, and patient engagement will be studied.
- Conditions
- Psoriasis, Atopic Dermatitis, Acne
- Trial name
- NCT04633616
- Testing
- Tailored Patient-Provider Communication, Non-Tailored Patient-Provider Communication
- Where
- United States
- Volunteers
- 134 people, healthy volunteers welcome
- Sponsor
- University of Southern California
Rheumatoid Arthritis, Psoriatic Arthritis
Prospective Longitudinal Effects of Intra-articular Corticosteroid Injection on Synovial Fluid Oxygen
Inflammatory arthritis such as rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are characterized by synovial inflammation of joints, potentially leading to joint destruction and functional disability.
- Trial name
- POLO (NCT04804449)
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- University of Oxford
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.